1 minute; and finally a final extension for 5 minutes at 72°C. Equal volume of PCR product for each sample was run on 2% w/v agarose gel and the image was obtained using biorad GelDoc XR+ imaging system. The intensity is quantified using ImageJ. [1] The primer sequences and annealing temperatures are listed in Supplementary Table 9 .
MiRNA Localization and CpG Island Identification
The genomic localization of miRNAs were investigated using UCSC genome browser under Genome Reference Consortium Human Build 37 (GRCh37/hg19). CpG islands were predicted by the CpG island track in UCSC or by Methyl Primer Express software using DNA sequences 10 kilobase upstream and downstream of the pre-miRNA sequence, using the following three criteria: 1. GC content of 50% or higher; 2. Length greater than 200bp; 3. Ratio greater than 0.6 of observed number of CG dinucleotides to the expected number on the basis of the number of Gs and Cs in the segment. [2] Supplementary Figure S1 . Validation of upregulation after 5'azacytidine treatment for six miRNAs by Taqman miRNA assay Supplementary Figure S2 . Methylation-Specific PCR of representative leading candidate TS-miRNAs. The intensity of bands were quantified using ImageJ as per user manual of the software. Supplementary Table S1 . Result of miRNA microarray: 74 miRNAs commonly upregulated by 5'aza, sorted by chromosomal location Supplementary Table S2 . Methylation status of miRNA-associated CpG sites in MM patients and healthy controls. P-value was calculated using T-Test comparing beta value of patients and normal controls.
Supplementary Table S3 . 215 Predicted miRNA targets that are also overexpressed in Myeloma patients compared with normal plasma cells (UAMS dataset GSE2658, cutoff q-value 0.005) Supplementary Table S4 . Upregulated genes in MM that are predicted to be the target of leading candidate TS-miRNAs, and their relevance in cancer in current literature Supplementary Table S5 . GSEA analysis, using the 215 predicted miRNA targets that are also upregulated in MM patients Supplementary 
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